A New Paradigm in Drug Development - The mission of Bio-Path is to make its neutral lipid delivery the standard delivery technology for antisense therapeutics in the pharmaceutical industry.
Liposomal Grb-2 Clinical Trial

Bio-Path completed the fifth cohort and has treated two patients in the sixth cohort of the Phase I clinical trial evaluating Liposomal Grb-2 in blood cancers.  The drug’s safety profile continues to be favorable with no treatment-related serious adverse events reported and data suggests possible anti-leukemia activity. The clinical trial is being conducted at the MD Anderson Cancer Center. The Company anticipates completing enrollment of the sixth cohort in the first quarter of 2014.

In addition, Bio-Path announced its intent to conduct three Phase II clinical trials of Liposomal Grb-2 salvage therapy in combination with frontline therapy in three different leukemia disease types: AML, CML and MDS. The Company anticipates starting this phase of development in the first half of 2014.

Latest News

Apr 3, 2014
Zacks Small-Cap Research Analysis Report

Apr 1, 2014
Bio-Path Holdings Reports Fiscal Year 2013 Operational and Financial Results

Mar 26, 2014
Bio-Path Holdings, Inc. Appoints Ulrich M. Mueller Chief Operating Officer

Mar 5, 2014
Bio-Path Holdings Announces Uplisting to the NASDAQ Capital Market